Allele frequency of CYP2C9 gene polymorphisms in Iran

Thrombosis and Haemostasis

Volumn 88, Issue 5, 2002, Pages 874-875

  Peyvandi, Flora ^a   Spreafico, M ^a   Karimi, M ^a   Zeinali, S ^a   Mannucci, P M ^a   Bianchi Bonomi, A ^a  

^a Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450 2C9; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ALLELE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG TOXICITY; ETHNIC DIFFERENCE; ETHNIC GROUP; EUROPE; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE DETECTION; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; IRAN; LETTER; MALE; MEDITERRANEAN SEA; MIDDLE EAST; NORMAL HUMAN; NORTH AMERICA; POPULATION RESEARCH; PRIORITY JOURNAL; SIDE EFFECT; UNITED KINGDOM; GENETICS; MEDICAL RECORD;

ARYL HYDROCARBON HYDROXYLASES; GENE FREQUENCY; HUMANS; IRAN; MEDICAL RECORDS; POLYMORPHISM, GENETIC;

EID: 0036845604     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613318     Document Type: Letter

References (10)

1. Miners J, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 535-8.
2. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-9.
3. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P4502C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
4. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9.
5. Garcìa-Martìn E, Martìnez C, Ladero JM, Gamito FJG, Agùndez JAG. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 2001; 57: 47-9.
6. Aynacioglu AS, Brockmöller J, Bauer S, Sachse C, Güzelbey P, Öngen Z, Nacak M, Roots I. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-15.
7. Ackermann E, Cascorbi I, Sachse C, Brocmoller J, Mrozikiewiza PM, Roots I. Frequencies and the allelic linkage of CYP2C9 mutations in a German population and the detection of a C/T mutation in intron 2. Eur J Clin Pharmacol 1997; 52: A71.
8. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52: 447-50.
9. Yasar Ü, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254: 628-31.
10. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJJ, Stein CM, Wilkinson GR, Schwartz UI. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African-Americans. Mol Pharmacol 2001; 60: 382-7.